Hims & Hers Health, Inc. (HIMS) Stock Analysis
Healthcare · Drug Manufacturers - Specialty & Generic · NYSE
Hims & Hers Health, Inc. (HIMS) posted $2.35B in revenue for fiscal 2025 (up 59.0% year over year), at a 5.5% net margin, and has compounded revenue about 73.6%/yr over five years, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Hims & Hers Health, Inc.
Hims & Hers Health, Inc. has grown revenue from $82.56M to $2.35B over the last 7 fiscal years, compounding about 73.6% a year. The most recent year was up 59%, so growth has cooled from its longer-run pace.
Net margin sits at 5.5%, down 3 points year over year on a 73.8% gross margin.
At today's valuation the market is pricing in roughly 31.6% annual free-cash-flow growth. The one thing worth a second look in the filings is receivables growing faster than sales.
Synthesised from Hims & Hers Health, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Hims & Hers Health, Inc. revenue & earnings — last 7 fiscal years
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $82.56M | $148.76M | $271.88M | $526.92M | $872.00M | $1.48B | $2.35B |
| Gross profit | $44.60M | $109.45M | $204.49M | $408.72M | $714.95M | $1.17B | $1.73B |
| Net income | $-72.06M | $-18.11M | $-107.66M | $-65.68M | $-23.55M | $126.04M | $128.37M |
| Net margin | -87.3% | -12.2% | -39.6% | -12.5% | -2.7% | 8.5% | 5.5% |
Source: Hims & Hers Health, Inc. SEC filings (10-K).
Hims & Hers Health, Inc.: 1 potential red flag in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Receivables growing faster than salesAccounts receivable rose 426.2% while revenue rose 59.0% in the latest year — a gap that can signal looser credit terms or pulled-forward sales. Worth checking days-sales-outstanding.
What growth is priced into HIMS stock?
At today's market cap of $6.48B, Hims & Hers Health, Inc. is priced for free-cash-flow growth of about 31.6% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $57.41M from the FY ending 2025-12-31). For comparison, revenue 73.6%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 7 years of Hims & Hers Health, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track HIMS in your portfolio →
Hims & Hers Health, Inc. financial history by metric
Compare Hims & Hers Health, Inc. with peers
About Hims & Hers Health, Inc.
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. Hims & Hers Health, Inc. is based in San Francisco, California.
Hims & Hers Health, Inc. — frequently asked questions
What is Hims & Hers Health, Inc.'s revenue?
Hims & Hers Health, Inc. (HIMS) reported revenue of $2.35B for fiscal year 2025, up 59.0% from the prior year, according to its SEC filings.
Is Hims & Hers Health, Inc. profitable?
Yes. HIMS earned net income of $128.37M in fiscal 2025, a net margin of 5.5%.
What is HIMS's P/E ratio?
Hims & Hers Health, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Hims & Hers Health, Inc. growing?
HIMS's revenue grew at roughly 73.6% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Hims & Hers Health, Inc. have?
As of fiscal year 2025, HIMS carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Hims & Hers Health, Inc.'s gross margin?
HIMS's gross margin was 73.8% in fiscal 2025 — gross profit of $1.73B on revenue of $2.35B.
What is Hims & Hers Health, Inc.'s market cap?
Hims & Hers Health, Inc. (HIMS) has a market capitalization of about $6.48B, based on the latest data in our nightly-refreshed cache.
When does Hims & Hers Health, Inc.'s fiscal year end?
HIMS's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into HIMS stock?
At today's market cap of $6.48B, Hims & Hers Health, Inc. is priced for free-cash-flow growth of about 31.6% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $57.41M from the FY ending 2025-12-31). For comparison, revenue 73.6%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Hims & Hers Health, Inc.'s official SEC filings (10-K and 10-Q), covering 7 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.